Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vandetanib + bicalutamide
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**vandetanib + bicalutamide** is a fixed-dose combination of two oral small molecule drugs: vandetanib, a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET kinases; and bicalutamide, a nonsteroidal antiandrogen that acts as an androgen receptor antagonist. The combination was investigated for treatment of metastatic castration-resistant prostate cancer (mCRPC), aiming to simultaneously block angiogenic, proliferative, and androgen-signaling pathways. In phase II trials, the combination did not show efficacy superior to bicalutamide alone and was associated with increased toxicity, leading to discontinuation of further development for this indication[1][2].
- Other names
- vandetanibbicalutamide
02
Targets
AR (Adrenergic receptors)EGFR (Epidermal growth factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on vandetanib + bicalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vandetanib + bicalutamide.